TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Exercise capacity measured by 6-minutes walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Tolerization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of HIV-1 infected CD4+ T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Radiographic progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in the WOMAC pain subscale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Extension of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in nasal nitric oxide (NO) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tissue pharmacodynamic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative sleep disordered breathing
Endpoint domain: Adverse events/effects
Primary endpoint: Relapse of Crohn's Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Heart Rate Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Actigraphy Sleep Efficiency (aSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Sleep Fragmentation Index (SFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Duration of Wake Bouts (aMeanDurWB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose of sorafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toxicities associated with the combination of topotecan and sorafenib
Endpoint domain: Adverse events/effects
Primary endpoint: Variation in the intensity of pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Who Had Complete Healing of EE by Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Maintained Complete Healing of EE at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Confirmed Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall post-ERCP pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Absolute value of tissue oxygenation saturation (StO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute value of tissue oxygenation saturation (StO2) rate of change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute value of tissue oxygenation saturation (StO2) amount of change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time 0 extrapolated to infinity (AUC[0-inf])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Depression Score on the Beck Depression Inventory (BDI-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mean Clinic Systolic and Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Comparison of Mean Home Systolic and Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 30-second-chair-stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Assay Negativity Rate (ANR) for Ebola Virus During the Treatment Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean Assay Negativity Rate (ANR) for Ebola Virus During the Follow-up Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cumulative flare rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptoms (palpitations)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in mean number of alcohol units consumed per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of Treg response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anterior patellar offset ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of RoActemra/Actemra
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration of RoActemra/Actemra
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Lens Preference Based on Subjective Comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: QT Interval Corrected for Heart Rate (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxygen extraction fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional improvement measured by change in six-minute walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Nocturia Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Benefit Based on Nocturia Quality of Life (NQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: change in daytime average systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to First Bowel Movement After Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Neurodevelopmental Outcome Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to Healing of All Non-aborted Genital Herpes Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clearance rate of Genital Warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Phenolic compound bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients reported experience measure (PREM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to re-admission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Taking Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: long-term safety
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of time within SpO2 target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Expression of granzymes and perforin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in urine albumin excretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of patients with a pCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Atrial arrhythmia burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of participants with improvement of clinical condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wet AMD development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Correlation of Banyan UCH-L1/GFAP Detection Assay with acute intracranial lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levels of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lean tissue mass (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical success at Month 120
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle microvascular blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: End of Treatment Virologic Response (EVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pulmonary Function Test (PFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Performance Upper Limb (PUL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Observed Oculocardiac Reflex (OCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Percentage of Diary-Recorded Heartburn-Free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maternal and infant block failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Counts of Endothelial Progenitor Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cardiovascular Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Type and Severity of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Arisen of EC in the CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Infection outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: SUSARs
Endpoint domain: Adverse events/effects
Primary endpoint: Metabolite Concentrations in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects Reported at Least One Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Wound Closure Responder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to Wound Closure Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of volunteers who become parasitemic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Occurrence of related Grade 3 adverse events and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: KCTD expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic failure at all time intervals from ART initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence measured by pill counts
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Functional Independence Scale (FIM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ottowa Sitting Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracranial Clinical Benefit Rate (CBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the percentage of endocervical CD4+ T cells susceptible to HIV pseudovirus entry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the number of endocervical CD4+ T cells susceptible to HIV pseudovirus entry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Øresland Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with adverse events and/or dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Concordance rate between ICGR-15 and Portal Pressure values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance calculated by the Tinetti test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance calculated by the one footed stationary test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of balance calculated by the NintendoTM Wii console
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of urea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of ß2-m
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of diclofenac epolamine patch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Trial Outcome Index (TOI) of FACT-B questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Response Rates by Blade Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician Administered PTSD Scale (CAPS - 5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: a/b ratio from Photoplethysmography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Confirmed cases of Covid-19
Endpoint domain: Mortality/survival
Primary endpoint: Failure of intravenous placement on the first attempt
Endpoint domain: Adverse events/effects
Primary endpoint: Pain/ache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Marijuana Inhales Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for Invasive Mechanical Ventilation
Endpoint domain: Mortality/survival
Primary endpoint: All-cause Death by Day 28
Endpoint domain: Mortality/survival
Primary endpoint: Prolonged abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cotinine-validated point-prevalence abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: central 5-HT6 receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of subjects achieving ASAS 20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of Intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Accrual rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Smokers' willingness to provide saliva
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection of biofilm infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: rate of HCC occurrence
Endpoint domain: Mortality/survival
Primary endpoint: liver related-death
Endpoint domain: Mortality/survival
Primary endpoint: Sensor Glucose readings within target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnosis of MAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of hepatic steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of significant hepatic fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Mayo score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-diastolic velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduced wound size in sqcm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Screening rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Treatment rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Experiencing Severe or Life Threatening Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal distance walked in 6 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supportive care needs and preferences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Global Impression Scale for Somatization Disorder
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: occurrence of intracranial haemorrhage leading to hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: occurrence of gastrointestinal bleeding leading to hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: occurrence of urogenital bleeding leading to hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of chemotherapy related adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: systolic aortic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: diastolic aortic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variability of FDG uptake measured by SUVmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability of FDG uptake measured by SUVpeak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability of diffusion-weighted imaging measured by difference in mean ADC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability of diffusion-weighted imaging measured by differences in minimum ADC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician Global Impressions - Improvement (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infectious focus 18F-FDG activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total Mandibular Length (Co-Gn)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Spinal Cord Independence Measure (SCIM) Version III Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quantity of organisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-month culture conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to maximum tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Had Any Adverse Events (AEs) During 24 Weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Had Any AEs During 52 Weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Had Any Serious Adverse Events (SAEs) During 24 Weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Had Any SAEs During 52 Weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Participants With At Least One Treatment-Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Achieving a Partial or Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum levels of direct bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of liver enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of carnitine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum levels of total bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle recruitment as a percentage of the maximal voluntary isometric contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Microneutralization Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: OCD severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of PE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Positive and Negative Syndrome Scale (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial fibrillation recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence and severity of drug-related adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of patient administered tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving Culture Conversion by Month 6
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Achieving Durable Culture Conversion Through 3 Months Off Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Systolic Blood Pressure Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic Blood Pressure Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Follicular fluid Placental Growth Factor (PlGF) Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes